مروری بر سلول‌های بنیادی مزانشیمی و عملکرد آن‌ها در پاسخ به عفونت

نوع مقاله : مقاله مروری

نویسندگان

1 دانشجوی کارشناسی ارشد، گروه ایمنی‌شناسی، دانشکده‌ی علوم پزشکی، دانشگاه تربیت مدرس، تهران، ایران

2 استادیار، گروه ایمنی‌شناسی، دانشکده‌ی علوم پزشکی، دانشگاه تربیت مدرس، تهران، ایران

3 استاد، گروه ایمنی‌شناسی، دانشکده‌ی علوم پزشکی، دانشگاه تربیت مدرس، تهران، ایران

چکیده

مقدمه: توانایی نوسازی، چند توانی و ویژگی تنظیم ایمنی، سلول‌های بنیادی مزانشیمی را به کاندیدای مناسبی برای سلول‌درمانی مبدل ساخته است. به تازگی، Mesenchymal stem cells (MSCs) و ترشحات آن‌ها در کنترل بیماری‌های عفونی مورد توجه قرار گرفته‌اند. MSCs، می‌تواند پاتوژن را بشناسد، به محل عفونت حرکت کند و با جهت‌دهی پاسخ‌های ایمنی و تولید پپتیدهای ضد میکروبی، با آن‌ها مبارزه کند. مطالعه‌ی مرورری حاضر با هدف بررسی نقش درمانی MSCs در بیماری‌های عفونی انجام شد.روش‌ها: این مطالعه به صورت مروری و با جستجوی واژگان کلیدی MSCs، میان‌کنش MSCs و سلول‌های سیستم ایمنی، نقش MSCs در عفونت و سلول‌درمانی بیماری‌های عفونی با MSCs در پایگاه‌های اطلاعاتی PubMed، Science Direct، Scopus و موتور جستجوگر Google scholar انجام شد. در نهایت، 100 مقاله انتخاب و بررسی شدند.یافته‌ها: بر اساس مطالعات انجام شده، MSCs‌درمانی یک روش امیدوار کننده در کنترل بیماری‌های عفونی می‌باشد. MSCs می‌تواند با هر دو سیستم ایمنی میزبان و پاتوژن میان‌کنش دهد. حاصل این میان‌کنش، ایجاد پاسخ‌های التهابی و ضد التهابی، ترشح پپتیدهای ضد میکروبی و تأثیر بر تمایز و عملکرد سلول‌های ایمنی است.نتیجه‌گیری: اثرات مثبت و منفی MSCs در هدایت پاسخ‌های ایمنی به دفعات تزریق، مرحله‌ی عفونت و تحریک گیرنده‌های MSCs بستگی دارد. بنابراین، انجام مطالعات فراگیر جهت ارایه‌ی راه‌کار درمانی مناسب در هر بیماری عفونی ضروری است

کلیدواژه‌ها

عنوان مقاله [English]

A Review on Mesenchymal Stem Cells and Their Function in Response to Infection

نویسندگان [English]

  • Elham Zanganeh 1
  • Sara Soudi 2
  • Ahmad Zavaran hosseini 3
1 MSc Student, Department of Immunology, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran
2 Assistant Professor, Department of Immunology, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran
3 Professor, Department of Immunology, School of Medical Sciences, Tarbiat Modares University, Tehran, Iran
چکیده [English]

Background: Self-renewal, multipotent, and immunomodulatory are properties of mesenchymal stem cells (MSCs) that make them a good candidate for cell therapy. Recently, MSCs and their secretions are considered in control of infectious disease. MSCs can recognize pathogens, migrate to infection site, and fight against them by redirecting immune responses and anti-microbial peptide secretion. In this review, the therapeutic role of MSCs in infectious disease is discussed.Methods: In this review article, we searched MSCs, interaction of MSCs and immune cells, MSCs in infection, and MSCs therapy in infectious disease as key words in valid databases including PubMed, Science Direct, Scopus, and Google scholar. Finally, 100 articles were selected and reviewed completely.Findings: According to the studies, MSCs therapy is a promising method for control of infectious disease. MSCs interact with both host immune systems and pathogen. The result of this interaction is inflammatory and anti-inflammatory responses, secretion of antimicrobial peptides, and influence on the differentiation and function of immune cells.Conclusion: Positive and negative effects of MSCs in the direction of immune response depend on the number of injections, infection phase, and stimulation of MSCs receptors. Therefore, comprehensive studies are needed to represent effective therapeutic protocols for any infectious disease.

کلیدواژه‌ها [English]

  • Mesenchymal stem cells
  • Infection
  • Inflammation
  • Cell therapy

مراجع

  1. Castro-Manrreza ME, Montesinos JJ. Immunoregulation by mesenchymal stem cells: Biological aspects and clinical applications. J Immunol Res 2015; 2015: 394917.
  2. Le BK, Davies LC. Mesenchymal stromal cells and the innate immune response. Immunol Lett 2015; 168(2): 140-6.
  3. Fan L, Hu C, Chen J, Cen P, Wang J, Li L. Interaction between mesenchymal stem cells and B-cells. Int J Mol Sci 2016; 17(5): E650.
  4. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105(4): 1815-22.
  5. Bouwman LI. Microbial ligands alter the fate of stem cells [MSc Thesis]. Utrecht, Netherlands: Utrecht University; 2009.
  6. Li W, Ren G, Huang Y, Su J, Han Y, Li J, et al. Mesenchymal stem cells: a double-edged sword in regulating immune responses. Cell Death Differ 2012; 19(9): 1505-13.
  7. Bernardo ME, Fibbe WE. Mesenchymal stromal cells: Sensors and switchers of inflammation. Cell Stem Cell 2013; 13(4): 392-402.
  8. Wang Y, Chen X, Cao W, Shi Y. Plasticity of mesenchymal stem cells in immunomodulation: Pathological and therapeutic implications. Nat Immunol 2014; 15(11): 1009-16.
  9. Alcayaga-Miranda F, Cuenca J, Khoury M. Antimicrobial activity of mesenchymal stem cells: Current status and new perspectives of antimicrobial peptide-based therapies. Front Immunol 2017; 8: 339.
  10. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008; 8(9): 726-36.
  11. Ankrum J, Karp JM. Mesenchymal stem cell therapy: Two steps forward, one step back. Trends Mol Med 2010; 16(5): 203-9.
  12. Keating A. Mesenchymal stromal cells: new directions. Cell Stem Cell 2012; 10(6): 709-16.
  13. Squillaro T, Peluso G, Galderisi U. Clinical trials with mesenchymal stem cells: An update. Cell Transplant 2016; 25(5): 829-48.
  14. Glenn JD, Whartenby KA. Mesenchymal stem cells: Emerging mechanisms of immunomodulation and therapy. World J Stem Cells 2014; 6(5): 526-39.
  15. Ullah I, Subbarao RB, Rho GJ. Human mesenchymal stem cells - current trends and future prospective. Biosci Rep 2015; 35(2).
  16. Parekkadan B, Milwid JM. Mesenchymal stem cells as therapeutics. Annu Rev Biomed Eng 2010; 12: 87-117.
  17. Ma S, Xie N, Li W, Yuan B, Shi Y, Wang Y. Immunobiology of mesenchymal stem cells. Cell Death Differ 2014; 21(2): 216-25.
  18. Ryan JM, Barry F, Murphy JM, Mahon BP. Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol 2007; 149(2): 353-63.
  19. Han X, Yang Q, Lin L, Xu C, Zheng C, Chen X, et al. Interleukin-17 enhances immunosuppression by mesenchymal stem cells. Cell Death Differ 2014; 21(11): 1758-68.
  20. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004; 103(12): 4619-21.
  21. Avanzini MA, Bernardo ME, Cometa AM, Perotti C, Zaffaroni N, Novara F, et al. Generation of mesenchymal stromal cells in the presence of platelet lysate: A phenotypic and functional comparison of umbilical cord blood- and bone marrow-derived progenitors. Haematologica 2009; 94(12): 1649-60.
  22. Dostert G, Mesure B, Menu P, Velot E. How do mesenchymal stem cells influence or are influenced by microenvironment through extracellular vesicles communication? Front Cell Dev Biol 2017; 5: 6.
  23. Ghahremani PM, Soudi S, Ghanbarian H, Bolandi Z, Namaki S, Hashemi SM. Effect of efferocytosis of apoptotic mesenchymal stem cells (MSCs) on C57BL/6 peritoneal macrophages function. Life Sci 2018; 212: 203-12.
  24. Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006; 107(1): 367-72.
  25. Tabera S, Perez-Simon JA, Diez-Campelo M, Sanchez-Abarca LI, Blanco B, Lopez A, et al. The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes.
  26. Haematologica 2008; 93(9): 1301-9.
  27. Comoli P, Ginevri F, Maccario R, Avanzini MA, Marconi M, Groff A, et al. Human mesenchymal stem cells inhibit antibody production induced in vitro by allostimulation. Nephrol Dial Transplant 2008; 23(4): 1196-202.
  28. Rosado MM, Bernardo ME, Scarsella M, Conforti A, Giorda E, Biagini S, et al. Inhibition of B-cell proliferation and antibody production by mesenchymal stromal cells is mediated by T cells. Stem Cells Dev 2015; 24(1): 93-103.
  29. Del Fattore A, Luciano R, Pascucci L, Goffredo BM, Giorda E, Scapaticci M, et al. Immunoregulatory effects of mesenchymal stem cell-derived extracellular vesicles on T lymphocytes. Cell Transplant 2015; 24(12): 2615-27.
  30. Hsu WT, Lin CH, Chiang BL, Jui HY, Wu KK, Lee CM. Prostaglandin E2 potentiates mesenchymal stem cell-induced IL-10+IFN-gamma+CD4+ regulatory T cells to control transplant arteriosclerosis. J Immunol 2013; 190(5): 2372-80.
  31. Le Blanc K, Rasmusson I, Gotherstrom C, Seidel C, Sundberg B, Sundin M, et al. Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes. Scand J Immunol 2004; 60(3): 307-15.
  32. Groh ME, Maitra B, Szekely E, Koc ON. Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp Hematol 2005; 33(8): 928-34.
  33. Ramasamy R, Tong CK, Seow HF, Vidyadaran S, Dazzi F. The immunosuppressive effects of human bone marrow-derived mesenchymal stem cells target T cell proliferation but not its effector function. Cell Immunol 2008; 251(2): 131-6.
  34. Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A, et al. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006; 24(2): 386-98.
  35. Spaggiari GM, Moretta L. Cellular and molecular interactions of mesenchymal stem cells in innate immunity. Immunol Cell Biol 2013; 91(1): 27-31.
  36. Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006; 24(1): 74-85.
  37. Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD, et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005; 105(10): 4120-6.
  38. Nauta AJ, Kruisselbrink AB, Lurvink E, Willemze R, Fibbe WE. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J Immunol 2006; 177(4): 2080-7.
  39. Spaggiari GM, Abdelrazik H, Becchetti F, Moretta L. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood 2009; 113(26): 6576-83.
  40. Zhang W, Ge W, Li C, You S, Liao L, Han Q, et al. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev 2004; 13(3): 263-71.
  41. Spees JL, Lee RH, Gregory CA. Mechanisms of mesenchymal stem/stromal cell function. Stem Cell Res Ther 2016; 7(1): 125.
  42. Hashemi SM, Hassan ZM, Pourfathollah AA, Soudi S, Shafiee A, Soleimani M. In vitro immunomodulatory properties of osteogenic and adipogenic differentiated mesenchymal stem cells isolated from three inbred mouse strains. Biotechnol Lett 2013; 35(1): 135-42.
  43. Hashemi SM, Hassan ZM, Pourfathollah AA, Soudi S, Shafiee A, Soleimani M. Comparative immunomodulatory properties of adipose-derived mesenchymal stem cells conditioned media from BALB/c, C57BL/6, and DBA mouse strains. J Cell Biochem 2013; 114(4): 955-65.
  44. Cuerquis J, Romieu-Mourez R, Francois M, Routy JP, Young YK, Zhao J, et al. Human mesenchymal stromal cells transiently increase cytokine production by activated T cells before suppressing T-cell proliferation: Effect of interferon-gamma and tumor necrosis factor-alpha stimulation. Cytotherapy 2014; 16(2): 191-202.
  45. Yousefi F, Ebtekar M, Soleimani M, Soudi S, Hashemi SM. Comparison of in vivo immunomodulatory effects of intravenous and intraperitoneal administration of adipose-tissue mesenchymal stem cells in experimental autoimmune encephalomyelitis (EAE). Int Immunopharmacol 2013; 17(3): 608-16.
  46. Ankrum JA, Ong JF, Karp JM. Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol 2014; 32(3): 252-60.
  47. Shirjang S, Mansoori B, Solali S, Hagh MF, Shamsasenjan K. Toll-like receptors as a key regulator of mesenchymal stem cell function: An up-to-date review. Cell Immunol 2017; 315: 1-10.
  48. Yang K, Wang J, Wu M, Li M, Wang Y, Huang X. Mesenchymal stem cells detect and defend against gammaherpesvirus infection via the cGAS-STING pathway. Sci Rep 2015; 5: 7820.
  49. Beutler B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature 2004; 430(6996): 257-63.
  50. Tomchuck SL, Zwezdaryk KJ, Coffelt SB, Waterman RS, Danka ES, Scandurro AB. Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses. Stem Cells 2008; 26(1): 99-107.
  51. Liotta F, Angeli R, Cosmi L, Fili L, Manuelli C, Frosali F, et al. Toll-like receptors 3 and 4 are expressed by human bone marrow-derived mesenchymal stem cells and can inhibit their T-cell modulatory activity by impairing Notch signaling. Stem Cells 2008; 26(1): 279-89.
  52. Opitz CA, Litzenburger UM, Lutz C, Lanz TV, Tritschler I, Koppel A, et al. Toll-like receptor engagement enhances the immunosuppressive properties of human bone marrow-derived mesenchymal stem cells by inducing indoleamine-2,3-dioxygenase-1 via interferon-beta and protein kinase R. Stem Cells 2009; 27(4): 909-19.
  53. Fiedler T, Salamon A, Adam S, Herzmann N, Taubenheim J, Peters K. Impact of bacteria and bacterial components on osteogenic and adipogenic differentiation of adipose-derived mesenchymal stem cells. Exp Cell Res 2013; 319(18): 2883-92.
  54. Waterman RS, Tomchuck SL, Henkle SL, Betancourt AM. A new mesenchymal stem cell (MSC) paradigm: Polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS One 2010; 5(4): e10088.
  55. Zheng G, Ge M, Qiu G, Shu Q, Xu J. Mesenchymal stromal cells affect disease outcomes via macrophage polarization. Stem Cells Int 2015; 2015: 989473.
  56. Sohni A, Verfaillie CM. Mesenchymal stem cells migration homing and tracking. Stem Cells Int 2013; 2013: 130763.
  57. Naaldijk Y, Johnson AA, Ishak S, Meisel HJ, Hohaus C, Stolzing A. Migrational changes of mesenchymal stem cells in response to cytokines, growth factors, hypoxia, and aging. Exp Cell Res 2015; 338(1): 97-104.
  58. Harman RM, Yang S, He MK, Van de Walle GR. Antimicrobial peptides secreted by equine mesenchymal stromal cells inhibit the growth of bacteria commonly found in skin wounds. Stem Cell Res Ther 2017; 8(1): 157.
  59. Krasnodembskaya A, Song Y, Fang X, Gupta N, Serikov V, Lee JW, et al. Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37. Stem Cells 2010; 28(12): 2229-38.
  60. Alcayaga-Miranda F, Cuenca J, Martin A, Contreras L, Figueroa FE, Khoury M. Combination therapy of menstrual derived mesenchymal stem cells and antibiotics ameliorates survival in sepsis. Stem Cell Res Ther 2015; 6: 199.
  61. Sung DK, Chang YS, Sung SI, Yoo HS, Ahn SY, Park WS. Antibacterial effect of mesenchymal stem cells against Escherichia coli is mediated by secretion of beta- defensin- 2 via toll- like receptor 4 signalling. Cell Microbiol 2016; 18(3): 424-36.
  62. Sutton MT, Fletcher D, Ghosh SK, Weinberg A, van HR, Kaur S, et al. Antimicrobial Properties of Mesenchymal Stem Cells: Therapeutic Potential for Cystic Fibrosis Infection, and Treatment. Stem Cells Int 2016; 2016: 5303048.
  63. Gupta N, Krasnodembskaya A, Kapetanaki M, Mouded M, Tan X, Serikov V, et al. Mesenchymal stem cells enhance survival and bacterial clearance in murine Escherichia coli pneumonia. Thorax 2012; 67(6): 533-9.
  64. Meisel R, Brockers S, Heseler K, Degistirici O, Bulle H, Woite C, et al. Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2,3-dioxygenase. Leukemia 2011; 25(4): 648-54.
  65. Isakson M, de Blacam C, Whelan D, McArdle A, Clover AJ. Mesenchymal stem cells and cutaneous wound healing: Current evidence and future potential. Stem Cells Int 2015; 2015: 831095.
  66. Lee DE, Ayoub N, Agrawal DK. Mesenchymal stem cells and cutaneous wound healing: novel methods to increase cell delivery and therapeutic efficacy. Stem Cell Res Ther 2016; 7: 37.
  67. Ochiai H, Kishi K, Kubota Y, Oka A, Hirata E, Yabuki H, et al. Transplanted mesenchymal stem cells are effective for skin regeneration in acute cutaneous wounds of pigs. Regen Ther 2017; 7: 8-16.
  68. Lee JW, Krasnodembskaya A, McKenna DH, Song Y, Abbott J, Matthay MA. Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria. Am J Respir Crit Care Med 2013; 187(7): 751-60.
  69. Monsel A, Zhu YG, Gennai S, Hao Q, Hu S, Rouby JJ, et al. Therapeutic effects of human mesenchymal stem cell-derived microvesicles in severe pneumonia in mice. Am J Respir Crit Care Med 2015; 192(3): 324-36.
  70. Chelluri LK, Prasad C, Vennila P, Alla G, Adavi V, Ratnakar K, et al. Preliminary report on immunomodulation of mesenchymal stem cells in M.tb infection. J Infect Dis 2010; 8(1): 1-4.
  71. Bhattacharya D, Dwivedi VP, Mona, Yadav V, Das G. Understanding the role of mesenchymal stem cells in infectious diseases: Focus on tuberculosis, malaria, sepsis and HIV. Electronic Journal of Biology 2016; 12(3): 247-53.
  72. Raghuvanshi S, Sharma P, Singh S, Van Kaer L, Das G. Mycobacterium tuberculosis evades host immunity by recruiting mesenchymal stem cells. Proc Natl Acad Sci USA 2010; 107(50): 21653-8.
  73. Joshi L, Chelluri LK, Gaddam S. Mesenchymal stromal cell therapy in MDR/XDR tuberculosis: A concise review. Arch Immunol Ther Exp (Warsz) 2015; 63(6): 427-33.
  74. Skrahin A, Ahmed RK, Ferrara G, Rane L, Poiret T, Isaikina Y, et al. Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial. Lancet Respir Med 2014; 2(2): 108-22.
  75. Matthay MA, Pati S, Lee JW. Concise review: mesenchymal stem (stromal) cells: Biology and preclinical evidence for therapeutic potential for organ dysfunction following trauma or sepsis. Stem Cells 2017; 35(2): 316-24.
  76. Mei SH, Haitsma JJ, Dos Santos CC, Deng Y, Lai PF, Slutsky AS, et al. Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. Am J Respir Crit Care Med 2010; 182(8): 1047-57.
  77. Yuan Y, Lin S, Guo N, Zhao C, Shen S, Bu X, et al. Marrow mesenchymal stromal cells reduce methicillin-resistant Staphylococcus aureus infection in rat models. Cytotherapy 2014; 16(1): 56-63.
  78. Thakur RS, Tousif S, Awasthi V, Sanyal A, Atul PK, Punia P, et al. Mesenchymal stem cells play an important role in host protective immune responses against malaria by modulating regulatory T cells. Eur J Immunol 2013; 43(8): 2070-7.
  79. Souza MC, Silva JD, Padua TA, Torres ND, Antunes MA, Xisto DG, et al. Mesenchymal stromal cell therapy attenuated lung and kidney injury but not brain damage in experimental cerebral malaria. Stem Cell Res Ther 2015; 6: 102.
  80. Jasmin, Jelicks LA, Koba W, Tanowitz HB, Mendez-Otero R, Campos de Carvalho AC, et al. Mesenchymal bone marrow cell therapy in a mouse model of Chagas disease. Where do the cells go? PLoS Negl Trop Dis 2012; 6(12): e1971.
  81. Silva DN, Souza BSF, Vasconcelos JF, Azevedo CM, Valim CXR, Paredes BD, et al. Granulocyte-colony stimulating factor-overexpressing mesenchymal stem cells exhibit enhanced immunomodulatory actions through the recruitment of suppressor cells in experimental chagas disease cardiomyopathy. Front Immunol 2018; 9: 1449.
  82. Xu HJ, Qian H, Zhu W, Zhang X, Yan YM, Zhang LL, et al. Inhibition of culture supernatant of mesenchymal stem cells on macrophages RAW264.7 activated by soluble egg antigen of Schistosoma japonicum. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi 2011; 29(6): 425-30. [In Chinese].
  83. Xu H, Qian H, Zhu W, Zhang X, Yan Y, Mao F, et al. Mesenchymal stem cells relieve fibrosis of Schistosoma japonicum-induced mouse liver injury. Exp Biol Med (Maywood) 2012; 237(5): 585-92.
  84. Noormehr H, Zavaran HA, Soudi S, Beyzay F. Enhancement of Th1 immune response against Leishmania cysteine peptidase A, B by PLGA nanoparticle. Int Immunopharmacol 2018; 59: 97-105.
  85. Soudi S, Hosseini AZ, Hashemi SM. Co-administration of rectal BCG and autoclaved Leishmania major induce protection in susceptible BALB/c mice. Parasite Immunol 2011; 33(10): 561-71.
  86. Khosrowpour Z, Hashemi SM, Mohammadi-Yeganeh S, Soudi S. Pretreatment of mesenchymal stem cells with Leishmania major soluble antigens induce anti-inflammatory properties in mouse peritoneal macrophages. J Cell Biochem 2017; 118(9): 2764-79.
  87. Dameshghi S, Zavaran-Hosseini A, Soudi S, Shirazi FJ, Nojehdehi S, Hashemi SM. Mesenchymal stem cells alter macrophage immune responses to Leishmania major infection in both susceptible and resistance mice. Immunol Lett 2016; 170: 15-26.
  88. Xu L, Gong Y, Wang B, Shi K, Hou Y, Wang L, et al. Randomized trial of autologous bone marrow mesenchymal stem cells transplantation for hepatitis B virus cirrhosis: regulation of Treg/Th17 cells. J Gastroenterol Hepatol 2014; 29(8): 1620-8.
  89. Lin BL, Chen JF, Qiu WH, Wang KW, Xie DY, Chen XY, et al. Allogeneic bone marrow-derived mesenchymal stromal cells for hepatitis B virus-related acute-on-chronic liver failure: A randomized controlled trial. Hepatology 2017; 66(1): 209-19.
  90. Salama H, Zekri AR, Medhat E, Al Alim SA, Ahmed OS, Bahnassy AA, et al. Peripheral vein infusion of autologous mesenchymal stem cells in Egyptian HCV-positive patients with end-stage liver disease. Stem Cell Res Ther 2014; 5(3): 70.
  91. Li L, Lim RZL, Lee LSU, Chew NSY. HIV glycoprotein gp120 enhances mesenchymal stem cell migration by upregulating CXCR4 expression. Biochim Biophys Acta Gen Subj 2018; 1862(8): 1790-800.
  92. Zhang Z, Fu J, Xu X, Wang S, Xu R, Zhao M, et al. Safety and immunological responses to human mesenchymal stem cell therapy in difficult-to-treat HIV-1-infected patients. AIDS 2013; 27(8): 1283-93.
  93. Mattar P, Bieback K. Comparing the immunomodulatory properties of bone marrow, adipose tissue, and birth-associated tissue mesenchymal stromal cells. Front Immunol 2015; 6: 560.
  94. Samsonraj RM, Rai B, Sathiyanathan P, Puan KJ, Rotzschke O, Hui JH, et al. Establishing criteria for human mesenchymal stem cell potency. Stem Cells 2015; 33(6): 1878-91.
  95. Lee S, Choi E, Cha MJ, Hwang KC. Cell adhesion and long-term survival of transplanted mesenchymal stem cells: a prerequisite for cell therapy. Oxid Med Cell Longev 2015; 2015: 632902.
  96. Saeedi P, Halabian R, Fooladi AAI. Antimicrobial effects of mesenchymal stem cells primed by modified LPS on bacterial clearance in sepsis. J Cell Physiol 2019; 234(4): 4970-86.
  97. Mello DB, Ramos IP, Mesquita FC, Brasil GV, Rocha NN, Takiya CM, et al. Adipose Tissue-derived mesenchymal stromal cells protect mice infected with trypanosoma cruzi from cardiac damage through modulation of anti-parasite immunity. PLoS Negl Trop Dis 2015; 9(8): e0003945.
  98. El-Shennawy SF, Abdel Aaty HE, Radwan NA, Abdel-Hameed DM, Alam-Eldin YH, El-Ashkar AM, et al. Therapeutic potential of mesenchymal stem cells on early and late experimental hepatic schistosomiasis model. J Parasitol 2015; 101(5): 587-97.
  99. Pereira JC, Ramos TD, Silva JD, de Mello MF, Pratti JES, da Fonseca-Martins AM, et al. Effects of Bone marrow mesenchymal stromal cell therapy in experimental Cutaneous leishmaniasis in BALB/c mice induced by Leishmania amazonensis. Front Immunol 2017; 8: 893.
  100. Yang R, Liu Y, Kelk P, Qu C, Akiyama K, Chen C, et al. A subset of IL-17(+) mesenchymal stem cells possesses anti-Candida albicans effect. Cell Res 2013; 23(1): 107-21.
  101. El-Ansary M, Abdel-Aziz I, Mogawer S, Abdel-Hamid S, Hammam O, Teaema S, et al. Phase II trial: Undifferentiated versus differentiated autologous mesenchymal stem cells transplantation in Egyptian patients with HCV induced liver cirrhosis. Stem Cell Rev 2012; 8(3): 972-81.
مجله دانشکده پزشکی اصفهان
دوره 37، شماره 522 - شماره پیاپی 522
خرداد و تیر 1398
صفحه 357-371

فایل ها

سابقه مقاله

  • تاریخ دریافت: 15 دی 1397
  • تاریخ بازنگری: 06 اردیبهشت 1403
  • تاریخ پذیرش: 17 فروردین 1401

هم رسانی

ارجاع به این مقاله

آمار